Hiromichi Nakajima

机构：National Cancer Center Hospital East · ORCID：0000-0001-6401-4258

发表论文 101 篇 · 总被引 2013 次 · h-index 21

代表论文

• Cyclophosphamide for anticancer therapy-induced interstitial lung disease in the modern era: a retrospective cohort study (2025 · Frontiers in Oncology · 被引 4)
• First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of 64 Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC). (2025 · Journal of Clinical Oncology · 被引 2)
• A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study. (2025 · Journal of Clinical Oncology · 被引 1)
• Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer (2025 · Breast Cancer · 被引 1)
• Clinical validation of plasma circulating-tumor DNA assay using highly sensitive Safe-SeqS technology for detecting RAS and BRAF V600E in metastatic colorectal cancer. (2025 · Journal of Clinical Oncology · 被引 1)
• The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer (2025 · Cancer Treatment and Research Communications · 被引 1)